RecruitingPhase 1Phase 2NCT07175493

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

Sponsor

Keymed Biosciences Co.Ltd

Enrollment

158 participants

Start Date

Nov 18, 2025

Study Type

INTERVENTIONAL

Conditions

Autoimmune Hemolytic Anemia Evans Syndrome Autoimmune Cytopenia Immune Thrombocytopenia (ITP)

Summary

To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CM336 Injection for people with autoimmune cytopenia, autoimmune hemolytic anemia, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.